Agilent Technologies Inc. and Imperial College London have signed a strategic scientific collaboration agreement that will see a broad range of Agilent instruments installed in a sponsored measurement suite to be housed within Imperial’s Molecular Sciences Research Hub.
Agilent Technologies Inc. (Santa Clara, California, USA) and Imperial College London have signed a strategic scientific collaboration agreement that will see a broad range of Agilent instruments installed in a sponsored measurement suite to be housed within Imperial’s Molecular Sciences Research Hub.
“Imperial College London plays a very important role in advancing a deeper understanding of the world through their lab instruction and research,” said Mike McMullen, Agilent President, and CEO. “We recognize the important contributions made by university scientific research to solve real-life challenges, from finding new ways to fight cancer, to ensuring the purity of food, to solving major environmental issues. It is an honour for Agilent to support Imperial in building an advanced scientific measurement and analytical laboratory on their new White City Campus. We value our partnership and look forward to taking this important step together,” he added.
Tony Cass, Professor of Chemical Biology in the Department of Chemistry and Institute of Biomedical Engineering at Imperial, has been appointed Director of the Agilent Measurement Suite. Cass will oversee the collaboration with an objective to develop and facilitate the translation of research, tools, and technology from academia to industry.
For more information, please visit: www.imperial.ac.uk and www.agilent.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.